|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
National Cancer Institute (NCI) |
|---|---|
| Information provided by: | National Institutes of Health Clinical Center (CC) |
| ClinicalTrials.gov Identifier: | NCT00061347 |
Purpose
To effectively treat prostate cancer, doctors need an accurate view (via X-rays) of the prostate gland during radiation therapy. To help improve this view, doctors may insert gold markers called fiducials into the prostate by placing hollow gold needles through the rectum and moving a fiducial through each needle. The purpose of the study is to determine whether an MRI scan can help doctors improve their placement of these needles.
Fifteen men will participate in this study. Patients will take the antibiotic levofloxacin for two days prior to the placement of the fiducials, then will have a small enema and another dose of the antibiotic on the morning of the procedure. After being anesthetized, patients will have an antenna-like tube placed into the rectum and have MRI images taken of the area. The doctor will then use these scans to place four fiducials into the prostate. The procedure will require approximately 45 minutes. Patients will be allowed to go home the same day of the procedure, which will be followed by a seven-week course of standard radiation therapy.
Prior to their participation in this study, patients will undergo the following evaluations: a physical exam, blood work, urine tests, and, if appropriate, an MRI or bone scan.
| Condition | Intervention | Phase |
|---|---|---|
|
Prostatic Neoplasms |
Drug: Levofloxacin Procedure: MRI |
Phase I |
| Study Type: | Interventional |
| Study Design: | Treatment |
| Official Title: | Trans-Rectal Placement of Prostatic Fiducial Markers Under MR-Guidance in Patients Receiving External Beam Radiotherapy for Prostate Cancer: A Pilot Study |
| Estimated Enrollment: | 15 |
| Study Start Date: | May 2003 |
| Estimated Study Completion Date: | February 2006 |
Effective image-guided prostate therapies require excellent visualization of the prostate and surrounding anatomy, such that cancerous tissue can be treated while avoiding nearby neural and vascular structures. As such, Magnetic Resonance Imaging is well suited for image-guidance because of its excellent soft tissue contrast, multiplanar capabilities, and the potential to yield spectral/biological tumor mapping. Despite the potential for MRI-guided prostate therapies, there are currently no techniques that allow for precise trans-rectal intraprostatic needle placement in patients.
In this pilot study we seek to validate the accuracy and tolerability of a new system and technique that allows for accurate placement of needles within the prostate based upon MR images. The method is very similar to transrectal ultrasound guided biopsy of the prostate, except that it is applicable within a closed high-field MRI scanner. Four gold fiducial markers will be placed within the prostate under needle guidance in a series of patients with localized prostate cancer before external beam radiotherapy. Fifteen patients will be enrolled onto this study with sample size determined to obtain reasonably precise estimates of mean placement accuracy. The accrual period is expected to be less than a year.
While placement of the fiducial markers has no direct therapeutic benefit for the patient, intraprostatic radiopaque fiducial markers (placed under ultrasound) have shown value in assessing daily setup errors and off-line organ motion during external beam radiation therapy for prostate cancer.
Therefore, a secondary objective is to gain experience using these intraprostatic fiducial markers for daily assessment and adjustment of external radiation beam targeting. These markers can also be utilized to aid in CT-MRI fusion and results in better target delineation for treatment planning.
In this way, prostate cancer patients who are receiving external-beam radiation therapy may benefit from participation.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Pathologically confirmed adenocarcinoma of the prostate gland.
Age greater than or equal to 18 years.
ECOG performance status of 0 or 1.
Informed consent: All patients must sign a document of informed consent indicating their understanding of the investigational nature and risks of the study before any protocol related studies are performed (this does not include routine laboratory tests or imaging studies required to establish eligibility).
EXCLUSION CRITERIA:
Patients with contraindication to transrectal needle placement:
Patients with contraindications to MRI:
Patients with chronic inflammatory bowel disease.
Patients with distant metastatic disease.
Patients with a prior history of pelvic or prostate radiotherapy.
Cognitively impaired patients who cannot give informed consent.
Other medical conditions deemed by the PI or associates to make the patient ineligible for protocol investigations, procedures, and high-dose external beam radiotherapy.
Contacts and Locations More Information
| Study ID Numbers: | 030190, 03-C-0190 |
| Study First Received: | May 23, 2003 |
| Last Updated: | June 19, 2006 |
| ClinicalTrials.gov Identifier: | NCT00061347 History of Changes |
| Health Authority: | United States: Federal Government |
|
Prostate Cancer Radiation Therapy MRI Fiducial Marker Prostate Cancer |
|
Anti-Bacterial Agents Prostatic Diseases Genital Neoplasms, Male Ofloxacin |
Anti-Infective Agents, Urinary Urogenital Neoplasms Genital Diseases, Male Prostatic Neoplasms |
|
Anti-Infective Agents Molecular Mechanisms of Pharmacological Action Genital Neoplasms, Male Prostatic Diseases Ofloxacin Anti-Infective Agents, Urinary Enzyme Inhibitors Urogenital Neoplasms Renal Agents |
Genital Diseases, Male Pharmacologic Actions Anti-Bacterial Agents Neoplasms Neoplasms by Site Therapeutic Uses Prostatic Neoplasms Nucleic Acid Synthesis Inhibitors |
